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Although renal osteodystrophy and vitamin D analogs may
be related to survival in maintenance hemodialysis (MHD)
patients, most studies have examined associations between
baseline values and survival without accounting for
variations in clinical and laboratory measures over time. We
examined associations between survival and quarterly
laboratory values and administered paricalcitol in a 2-year
(July 2001–June 2003) cohort of 58 058 MHD patients from all
DaVita dialysis clinics in USA using both time-dependent Cox
models with repeated measures and fixed-covariate Cox
models with only baseline values. Whereas hypercalcemia
and hyperphosphatemia were robust predictors of higher
death risk in all models, the association between serum
calcium and mortality was different in time-varying models.
Changes in baseline calcium and phosphorus values beyond
the Kidney Disease Outcome Quality Initiative recommended
targets were associated with increased mortality.
Associations between high serum parathyroid hormone and
increased death risk were masked by case-mix characteristics
of MHD patients. Time-varying serum alkaline phosphatase
had an incremental association with mortality.
Administration of any dose of paricalcitol was associated with
improved survival in time-varying models. Controlling for
nutritional markers may introduce overadjustment bias
owing to their strong collinearity with osteodystrophy
surrogates. Whereas both time-dependent and fixed-
covariate Cox models result in similar associations between
osteodystrophy indicators and survival, subtle but potentially
clinically relevant differences between the two models exist,
probably because fixed models do not account for variations
of osteodystrophy indices and changes in medication dose
over time.
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Renal osteodystrophy is a common complication of advanced
chronic kidney disease (stages 3–5) and may be associated
with disorders of mineral metabolism, coronary artery
calcifications, and poor survival, especially among those
who require maintenance dialysis treatment.1–5 Several recent
studies6–9 including a large epidemiologic study by Block
et al.10 have shown an association between indices of the
renal osteodystrophy management and mortality in main-
tenance hemodialysis (MHD) patients. However, virtually all
these studies have examined associations between the baseline
serum mineral values at the start of a given cohort and
subsequent survival not accounting for the changes in
concentrations of these measures and other covariates over
time. Blood concentrations of minerals (calcium and
phosphorus), parathyroid hormone (PTH), and alkaline
phosphatase may change greatly over time. Such changes may
be the result of variations in administered medications such
as vitamin D analogs or the type of phosphorus binders or
owing to longitudinal alterations in other biological factors
such as alterations in factors related to malnutrition–
inflammation–cachexia syndrome (MICS). Because the
medical management of MHD patients by clinicians is
usually based on repeated measurements of blood tests,
examining such associations using time-dependent models
that are not restricted to fixed baseline data but include
changes over time is more similar to real clinical scenarios
and may offer additional insights into this conundrum.
The epidemiologic study Block et al.10 examined survival
before the routine use of sevelamer hydrochloride and
paricalcitol, that is, the two most commonly used medica-
tions for the management of osteodystrophy dialysis patients
in the past few years.11 Similarly, the default dialysate calcium
concentration was 3.5 mEq/l in the past, but it has been
reduced to 2.5 mEq/l in most MHD patients since early
2000s. A number of important questions about renal
osteodystrophy have remained unanswered. It is not clear
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whether a fall or rise in serum calcium or phosphorus over
time has any association with subsequent survival indepen-
dent of the baseline calcium or phosphorus values.
We studied a large and contemporary national cohort of
MHD patients with repeated measures and with dialysate
calcium concentration of 2.5 in over 80% of patients. We
sought to examine whether the associations between
surrogates of renal osteodystrophy and survival are similar
in two different multivariate models: (1) time-dependent Cox
models using time-varying repeated measures and (2)
traditional Cox models with fixed covariates using only
baseline values at the start of the cohort. We also examined
the associations between changes in laboratory indices of
renal osteodystrophy and death risk over time.
RESULTS
A total of 69 819 MHD patients were identified during the 2
years of observation. After deleting patients who did not
remain beyond 3 months of MHD, that is, 5600 patients from
the first seven quarters and 5870 patients from the last
quarter, 58 349 MHD patients remained, of which 58 058
MHD patients had required data for the planned analyses.
The latter group included 37 049 patients (64%) from the
first calendar quarter data set (q1) and the rest from the
subsequent quarters (q2–q8). Table 1 shows baseline demo-
graphic, clinical, and laboratory characteristics of the MHD
patients during the first calendar quarter according to
vitamin D analog administration status. Approximately
32% of the patients did not receive any vitamin D analog
during the baseline quarter. A similar proportion was
observed in subsequent calendar quarters (data not shown).
Patients who did not receive a vitamin D analog were more
likely to be Caucasians, to have slightly lower serum albumin
and creatinine concentrations, and to receive lower doses of
recombinant human erythropoietin (rHuEPO). The admi-
nistered dialysate calcium concentration categories are not
shown in Table 1 and included: 1.5 mEq/l or lower (0.7%),
2.0 mEq/l (3.5%), 2.5 mEq/l (84.2%), 3.0 mEq/l (7.8%), and
3.5% or higher (3.7%).
Table 2 shows correlation coefficients of serum calcium
(not albumin adjusted) and phosphorus concentrations with
relevant clinical and laboratory measures at the baseline of
this cohort study. A higher serum albumin concentration was
associated with a higher serum calcium level. Patients with
higher serum phosphorus levels also had a higher serum
creatinine and intact PTH but a lower serum bicarbonate
concentration. However, most of these associations weakened
substantially after multivariate adjustments.
Figures 1–4 show the association between the albumin-
adjusted serum calcium, serum phosphorus, calcium–pho-
sphorus product, intact PTH and alkaline phosphatase
concentrations, and 2-year survival, respectively. Each figure
consists of two panels that depict relative risks of all-cause
mortality in fixed covariate (conventional) Cox models using
only baseline data (upper panels) and time-dependent Cox
models using time-varying repeated measure in up to eight
calendar quarters (lower panel). The fixed-covariate models
also include population frequency bar diagrams in the
background.
Hypocalcemia was associated with an increased death risk
in the unadjusted and case-mix adjusted models (reference
calcium group: 9–9.5 mg/dl); however, controlling for MICS
surrogates mitigated the association between low serum
calcium and death substantially. In contrast, hypercalcemia
Table 1 | Baseline (first calendar quarter) data of 58 058 MHD
patients (7/2001–6/2003), including 37 049 patients from the
first quarter (q1) and 21 009 patients from subsequent
quarters (q2–q8), divided into two groups based on the
administration of vitamin D analog (paricalcitol or calcitriol)
during the first calendar quarter
Variable
Received vitamin
D at baselinea
(n=39 305)
Did NOT receive
vitamin D at
baselinea
(n=18 753)
Age (years) 60715 61716
Gender (% women)** 46 46
Diabetes mellitus (%)** 45 45
Race and ethnicity
Caucasians (%) 32 48
Blacks (%) 38 20
Hispanics (%)* 18 17
Vintage (time on dialysis)
3–6 months (%) 42 40
Primary insurance
Medicare (%)** 60 60
Cohort time (days) 4697256 4267260
Body mass index (kg/m2)** 26.476.3 25.975.6
Dialysate calcium (mEq/l) 2.5570.28 2.5870.28
Kt/V (single pool)** 1.5370.31 1.5470.32
nPCR or nPNA (g/kg/day) 1.070.2 1.070.2
Serum albumin (g/dl) 3.7870.39 3.6870.45
Creatinine (mg/dl) 9.373.2 8.573.3
TIBC (mg/dl)** 202741 202744
Ferritin (ng/ml) 6107493 6027530
Iron (ng/ml)** 61726 60727
Iron saturation ratio (%) 31711 30712
Bicarbonate (mEq/l) 21.772.7 22.072.9
Phosphorus (mg/dl) 5.871.4 5.571.7
Calcium (mg/dl) 9.370.7 9.270.8
Albumin adj. calcium (mg/dl) 9.370.7 9.270.8
Alkaline phosphatase (U/l) 115786 112794
Intact PTH (pg/ml) 3747362 2287319
Ca–Phos product (mg2/dl2) 53.8713.6 50.5715.9
Blood hemoglobin (g/dl) 12.071.3 11.971.3
WBC ( 103/ml) 7.272.2 7.672.5
Lymphocyte (% of total WBC) 2178 2077
rHuEPO dose (U/week) 20 441716 847 18 729731 566
MHD, maintenance hemodialysis; nPCR, normalized protein catabolic rate; nPNA,
normalized protein nitrogen appearance; PTH, parathyroid hormone; rHuEPO,
recombinant human erythropoietin; TIBC, total iron-binding capacity; WBC, white
blood cells.
aBaseline period of the cohort pertains to the first 3 months (first calendar quarter of
the cohort)
*P-value between 0.05 and 0.001, ** P-value40.05, all other P-values are o0.001.
All P-values for the difference between the two groups areo0.001, unless specified.
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(48.5 mg/dl in the fixed-covariate model and 410.5 mg/dl
in the time-dependent model) continued to remain a strong
predictor of incrementally higher death risk (see Figure 1).
Similarly, hypophosphatemia was a strong correlate of death
high risk in both unadjusted and case-mix adjusted models
(reference phosphorus group: 5–6 mg/dl), but a large
proportion of this association was mitigated after controlling
for MICS. Hyperphosphatemia (46 mg/dl) was a strong
correlate of higher death risk in both models even after case-
mix and MICS adjustment (Figure 2). The calcium–pho-
sphorus product showed a similar trend with incrementally
higher death risks in multivariate adjusted models (reference
group: 45–50 mg2/dl2, see Figure 3).
In unadjusted models, only lower values of serum intact
PTH (o200 pg/ml) were associated with mortality, whereas
mortality risk of higher values (4300 mg/dl) did not differ
from the reference group of 200–300 pg/ml (see Figure 4).
However, multivariate adjustments disclosed a strong asso-
ciation between incrementally higher serum PTH values and
increased death risk. The association between serum alkaline
phosphatase (usual normal range: 25–150 u/l) and death risk
was more monotonic. Compared to the selected reference
group of 70–80 U/l, incrementally higher alkaline phospha-
tase values exhibited a relatively linear association with
higher death risks (Figure 5).
In order to investigate whether changes over time in
serum calcium, phosphorus and the calcium–phosphorus
product beyond Kidney Disease Outcome Quality Initiative
(K/DOQI) guidelines recommended ranges are associated
with changes in death risk independent of their baseline
values or other clinical or laboratory measures, Cox
regression modeling for these changes was examined in
those patients whose baseline values were within the K/DOQI
recommended ranges,12 that is, baseline albumin-adjusted
serum calcium between 8.4 and 9.5 mg/dl (n¼ 17 113),
baseline serum phosphorus between 3.5 and 5.5 mg/dl
(n¼ 13 184) and baseline calcium–phosphorus product
o55 mg2/dl2 (n¼ 18 423) (Figure 6). An excessive fall (or
rise) in serum calcium greater than 0.6 mg/dl in 6 months
was associated with higher death risk in patients whose
baseline value was within the K/DOQI recommended
calcium range (Figure 6, upper panel). A similar U-curve
association with mortality was also observed for excessive
changes in serum phosphorus (Figure 6, middle panel). An
incremental rise in serum calcium–phosphorus product
beyond 10 mg2/dl2 per 6 months was also associated with
progressively increasing death risks in MHD patients whose
baseline serum calcium–phosphorus product was within the
K/DOQI recommended range, that is,o55 mg2/dl2 (Figure 6,
lower panel).
In order to examine the association between the admin-
istration of paricalcitol and survival, we a priori classified
MHD patients into five groups according to the average dose
of paricalcitol administered within each calendar quarter of
the cohort after excluding those who received calcitriol
(Table 3). Patients who did not receive paricalcitol or received
Table 2 | Bivariate (unadjusted) and multivariate adjusted correlation coefficients between the quarterly averaged serum
calcium and phosphorus concentrations and some relevant variables at baseline in 58 058 MHD patients
Serum calcium Serum phosphorus
Variable
Pearson’s
correlation r
Multivariate adjusted
correlationa
Pearson’s
correlation r
Multivariate adjusted
correlationa
Age 0.01** +0.03 0.32 +0.01**
Kt/V +0.05 0.01* 0.14 0.02
BMI +0.02 0.02 +0.09 0.02
Serum albumin +0.31 +0.13 +0.17 +0.05
nPCR +0.01 +0.01** +0.23 +0.02
TIBC +0.11 +0.03 +0.08 +0.01
Ferritin +0.05 +0.01 0.05 0.01**
Bicarbonate +0.15 +0.06 0.35 0.02
Creatinine +0.12 +0.04 +0.42 +0.05
Intact PTH +0.01** 0.06 +0.33 0.02
Alkaline phosphatase 0.07 +0.02 0.01** +0.01*
Blood hemoglobin +0.11 +0.03 +0.03 +0.01*
WBC 0.02 +0.04 +0.02 +0.01
Lymphocyte % +0.09 +0.02 +0.02 +0.01**
Administered rHuEPO dose 0.07 +0.01** +0.04 +0.01**
Paricalcitol dose +0.15 +0.01** +0.17 0.03
Calcitriol dose 0.01** 0.01** 0.01 0.01**
BMI, body mass index; MHD, maintenance hemodialysis; nPCR, normalized protein catabolic rate; PTH, parathyroid hormone; rHuEPO, recombinant human erythropoietin;
TIBC, total iron-binding capacity; WBC, white blood cells.
aMultivariate models include all case-mix and MICS covariates.
**P-value 40.05; *P-value between 0.01 and 0.05; all other P-values are o0.01.
All P-values are o0.01 unless specified. Correlation coefficients 40.10 are in bold.
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low doses (between 1 and 5 mg/week) had the lowest baseline
serum PTH, whereas those who received incrementally higher
paricalcitol doses had higher baseline serum PTH concentra-
tions (Table 3). Figure 7 shows the association between
paricalcitol dose and mortality risk in 55 716 MHD patients,
that is, after excluding 2342 patients who received calcitriol at
least once during any given quarter. Receiving any dose of
paricalcitol was associated with greater survival as compared
to those who did not receive paricalcitol. However, among
those who received paricalcitol, those who required incre-
mentally higher doses showed a trend toward increased death
risk (Figure 7).
DISCUSSION
In a 2-year cohort of 58 058 MHD patients from one large
dialysis organization across the USA at the dawn of the
twenty-first century, we examined both fixed baseline and
time-varying associations between several factors related to
renal osteodystrophy and survival. Our findings include
associations that are both confirmatory of findings by other
investigators6–11,13 and novel associations that have not been
reported previously. These findings may further support
K/DOQI recommendations for the management of renal
osteodystrophy.12
Serum minerals and mortality
Higher serum calcium and phosphorus levels were consis-
tently associated with increased death risks, which is
consistent with recent findings by Block et al.7,10 and other
investigators who used non-time-dependent models.14,15 In
time-dependent models, higher a serum calcium threshold
(410.5 mg/dl) was associated with increased death risk,
whereas in non-time-dependent models, the mortality
predictability of hypercalcemia starts at lower calcium level
(48.5 mg/dl). Additional studies are needed to ascertain the
clinical relevance of such differences.
We also found that some of the naive associations
traditionally observed between lower serum calcium and
phosphorus levels and higher mortality risks16,17 may be
owing to the confounding effect of MICS and its association
with outcome (Figure 1). The pronounced association
between hypophosphatemia and death (Figure 2) can be
Al
l-c
au
se
 d
ea
th
 h
az
ar
d 
ra
tio
0
2000
4000
6000
8000
10 000
12 000
14 000
16 000
18 000
Corrected serum calcium (mg/dl)
Al
l-c
au
se
 d
ea
th
 h
az
ar
d 
ra
tio
0.8
1.5
2
1
unadjusted
case-mix
case-mix and MICS
Fixed-covariate model
with baseline values
Corrected serum calcium (mg/dl)
<8.
0
8.0
–
8.49
8.5
–
8.99
9.0
–
9.49
9.5
–
9.99
10.0
–
10.4
9
10.5
–
10.9
9

11.0
<8.
0
8.0
–
8.49
8.5
–
8.99
9.0
–
9.49
9.5
–
9.99
10.0
–
10.4
9
10.5
–
10.9
9

11.0
0.7
1.5
2
3
1
unadjusted
case-mix
case-mix and MICS
Time-dependent model
with repeated measures
Fr
eq
u
e
n
cy
Figure 1 | Association between albumin-adjusted serum calcium
values and the relative risk of death in 58 058 MHD patients over
a 2-year interval (July 2001–June 2003) using fixed-covariate Cox
modeling with only baseline values (upper panel) and time-
dependent Cox models with time-varying repeated measures
(lower panel). The fixed-covariate model also includes a background
bar diagram to reflect patient population frequency in each group.
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Figure 2 | Association between the time-varying serum phos-
phorus values and the relative risk of death in 58 058 MHD
patients over a 2-year interval (July 2001–June 2003) using fixed-
covariate Cox modeling with only baseline values (upper panel)
and time-dependent Cox models with time-varying repeated
measures (lower panel). The fixed-covariate model also includes a
background bar diagram to reflect patient population frequency in
each group.
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an indicator of poor nutritional intake.17,18 In contrast,
hyperphosphatemia remained a strong predictor of poor
survival even after MICS adjustment, consistent with
previous findings.10,15 The underlying association between
high calcium–phosphorus products, which was almost
entirely masked by case-mix characteristics of the patients
(Figure 3), was found to be monotonic and strictly up-going
after multivariate adjustments, similar to what that has been
reported previously using non-time-dependent models.10,15
In addition to examining the time-dependent associations
between the measured serum concentrations of the minerals
and mortality, we also found that changes over time in these
measures may have a bearing on survival (Figure 6). These
findings may verify the appropriateness of the K/DOQI
recommended ranges.
Serum PTH and survival
The lack of any association between high ranges of serum
PTH and mortality in MHD patients was masked almost
entirely by the case-mix characteristics of the patients
(Figure 4); this is consistent with a recent database analysis
by Block et al.10 If this association is causal, it may explain
why vitamin D analogs that lower the PTH level are
associated with better survival as reported by Teng et al.13
and also observed by ourselves in the current study. We also
found that lower levels of serum PTH, especially below the
K/DOQI recommended lower threshold (o150 pg/ml), are
associated with increased death risk (see Figure 4) as
indicated by others.19,20
Serum alkaline phosphatase and mortality
In this study, the association between serum alkaline
phosphatase and survival was also examined. This monotonic
and almost strictly up-going association independent of the
level of multivariate adjustment (Figure 5) is in sharp
contrast to the associations between minerals or PTH and
survival, which are U or J shaped (Figures 1–4). The K/DOQI
guidelines states that the deleterious effects of high serum
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Figure 3 | Association between the time-varying product of serum
calcium and phosphorus values and the relative risk of death in
58 058 MHD patients over a 2-year interval (July 2001–June 2003)
using fixed-covariate Cox modeling with only baseline values
(upper panel) and time-dependent Cox models with time-
varying repeated measures (lower panel). The fixed-covariate
model also includes a background bar diagram to reflect patient
population frequency in each group.
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Figure 4 | Association between the time-varying serum intact PTH
values and the relative risk of death in 58 058 MHD patients over
a 2-year interval (July 2001–June 2003) using fixed-covariate Cox
modeling with only baseline values (upper panel) and time-
dependent Cox models with time-varying repeated measures
(lower panel). The fixed-covariate model also includes a background
bar diagram to reflect patient population frequency in each group.
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PTH levels may be manifested by elevated bone alkaline
phosphatase activity owing to associated bone resorption.12
To that end, the correlation between alkaline phosphatase
and PTH was 0.27 in our study but much lower with serum
calcium (r¼ 0.09) and phosphorus concentration (r¼ 0.06).
However, the inclusion of PTH in the multivariate model did
not mitigate the monotonic association with death (data not
shown).
It is important to note that the alkaline phophatase
measured routinely in dialysis patients is not bone-specific.
Liver disease may be associated with increased serum alkaline
phosphatase level. Indeed, we found a moderate association
between alkaline phosphatase and the liver enzyme serum
glutamic oxaloacetic transaminase (aspartate aminotransfer-
ase) in our study (r¼ þ 0.29). However, even though liver
diseases such as hepatitis C are associated with increased liver
enzyme and with increased death risk in MHD patients,21 a
large proportion of the mortality predictability of alkaline
phosphatase is likely owing to renal osteodystrophy.
0
2000
4000
6000
8000
10 000
12 000
14 000
16 000
Alkaline phosphatase (U/l)
<50
50–
69.9
70–
89.9
90–
109
.9
110
–
129
.9
130
–
149
.9
150
–
169
.9
170
–
189
.9
190
–
209
.9

210
Alkaline phosphatase (U/l)
<50
50–
69.9
70–
89.9
90–
109
.9
110
–
129
.9
130
–
149
.9
150
–
169
.9
170
–
189
.9
190
–
209
.9

210
Al
l-c
au
se
 d
ea
th
 h
az
ar
d 
ra
tio
0.7
1.5
2
3
1
unadjusted
case-mix
case-mix and MICS
Fixed-covariate model
with baseline values
Al
l-c
au
se
 d
ea
th
 h
az
ar
d 
ra
tio
0.7
1.5
2
1
unadjusted
case-mix
case-mix and MICS
Time-dependent model
with repeated measures
Fr
eq
ue
nc
y
Figure 5 | Association between the time-varying serum alkaline
phosphatase values and the relative risk of death in 58 058 MHD
patients over a 2-year interval (July 2001–June 2003) using fixed-
covariate Cox modeling with only baseline values (upper panel)
and time-dependent Cox models with time-varying repeated
measures (lower panel). The fixed-covariate model also includes a
background bar diagram to reflect patient population frequency in
each group.
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Figure 6 | Association between the changes in albumin-adjusted
serum calcium (upper panel), serum phosphorus (middle panel),
and the product of serum calcium and phosphorus (lower panel)
during the first 6 months of the cohort (July 2001–12/2001) and
the subsequent 18-month (1/2002–June 2003) risk of all-cause
death in MHD patients. Note that the selected patients in
each panel are those with a baseline value within the K/DOQI
recommended range,12 that is, the baseline serum calcium value
of patients in the upper panels in between 8.4 and 9.5 mg/dl
(n¼ 17 113), the baseline serum phosphorus value of patients in
the middle panel is between 3.5 and 5.5 mg/dl (n¼ 13 184), and
the baseline serum Ca–Phos product of patients in the lower
panel is o55 mg2/dl2 (n¼ 18 423). Each panel also includes a
background bar diagram to reflect patient population frequency
in each group.
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Paricalcitol and survival
This study also confirms the recently reported association
between the administration of any dose of paricalcitol and
greater survival in MHD patients (Figure 7).13,22 In some
models and across some but not all paricalcitol dose groups,
requiring higher doses was associated with a trend toward
higher death risk (Figure 7). This inconsistent trend might be
owing to a higher baseline serum PTH level among those
who were administered higher paricalcitol doses.23,24 This
association may be somewhat analogous to what has been
described for rHuEPO in MHD patients, in whom requiring
higher doses of rHuEPO are associated with higher death
risk,25,26 possibly owing to the association of rHuEPO
resistance with inflammation.27
Strength and limitation of the study
Our study should be qualified because it is observational,
rather than interventional, and because a mixed incident/
prevalent MHD population was examined. Moreover, the
impact of therapy with sevelamer on renal osteodystrophy
cannot be examined by these analyses.28 Nevertheless, as
essentially all MHD patients of the DaVita dialysis facilities
were included in our analyses, the likelihood of selection bias
is minimal. Moreover, all dialysis facilities were under
uniform administrative care, and all laboratory tests were
performed in one single laboratory with optimal quality
assurance monitoring. Furthermore, we used 3-month
averaged measures rather than one single measure at baseline,
and we adjusted for dialysis vintage in all multivariate
models.
Similar to the study by Teng et al.13 as well as our previous
studies,29–32 we did not include history of cardiovascular or
other comorbidities as covariates. However, diabetes data
were available and adjusted for in all multivariate models.
Moreover, many case-mix and MICS covariates that were
included in the models are known to have strong associations
with comorbid conditions. The limited comorbidity data
used in some previous studies usually originated from the
dialysis initiation form (Form 2728), in which comorbid
conditions are significantly underreported33 and which is
outdated for prevalent patients with higher vintage periods.
Another limitation of our study is lack of explicit laboratory
markers of inflammation such as C reactive protein.
However, we did use data on serum albumin, ferritin, and
total iron binding capacity and blood WBC and rHuEPO
dose, all of which have known associations with inflamma-
tion. Finally, the studied cohort was before the calcimimetic
agent cinacalcet was approved by the Food and Drug
Administration.34 Hence, the relationship between osteody-
strophy and survival may be altered in patients receiving
cinacalcet starting 2004.
Table 3 | Selected categories of administered paricalcitol and 2-year mortality census [rate] among 58 058 MHD patients
Paricalcitol
(lg/week) Group size (%)
All-cause death
[%]
Cardio-vascular
death [%]
Baseline calcium
(mg/dl)
Baseline
phosphorus
(mg/dl)
Baseline PTH
(pg/ml)
Baseline albumin
(g/dl)
None given 20 663 (36) 5459 [26] 2196 [11] 9.2 (0.7) 5.5 (1.7) 238 (323) 3.69 (0.44)
1–4.9 5288 (9) 1326 [25] 558 [11] 9.2 (0.6) 5.4 (1.5) 229 (222) 3.73 (0.41)
5–9.9 11 965 (21) 2960 [25] 1346 [12] 9.2 (0.7) 5.6 (1.5) 277 (231) 3.76 (0.39)
10–14.9 8326 (14) 1998 [24] 878 [11] 9.3 (0.7) 5.9 (1.4) 358 (296) 3.77 (0.39)
X15.0 11 816 (20) 2786 [24] 1265 [11] 9.5 (0.8) 6.2 (1.4) 555 (476) 3.81 (0.37)
MHD, maintenance hemodialysis; PTH, parathyroid hormone.
Continuous values are in form of (mean7s.d.).
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Figure 7 | Association between the time-varying administered
dose of paricalcitol and the relative risk of death in 58 058 MHD
patients over a 2-year interval (July 2001–June 2003) using fixed-
covariate Cox modeling with only baseline values (upper panel)
and time-dependent Cox models with time-varying repeated
measures (lower panel). The fixed-covariate model also includes a
background bar diagram to reflect patient population frequency in
each group.
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Conclusions and clinical implications
Whereas both time-dependent and fixed-covariate Cox
models resulted in similar associations between osteodystro-
phy indicators and survival in many instances, subtle but
potentially clinically relevant differences between the two
models existed, probably because fixed models do not
account for variations of osteodystrophy indices and changes
in medication dose over time. Hence, time-dependent
models may be clinically more relevant, as they simulate
the real clinical scenarios, in which physicians evaluate and
manage the MHD patients.
Adjustment for MICS resulted in changes in the
magnitude and direction of some but not all associations.
Although such extensive multivariate adjustments may be
indicated, they may also introduce overadjustment bias,35,36
because there is a strong collinearity between MICS markers
and osteodystrophy surrogates (see Table 2) and because
MICS markers may be in the causal pathways that link
osteodystrophy to outcomes.37,38 Hence, whereas case-mix
adjustments appear appropriate, we caution against inter-
pretation of the associations after additional MICS adjust-
ment. Moreover, bias by indication may also have led to
patients with different death risk profiles being treated
differently, for example, patients with higher death risk may
not have received vitamin D analogs, leading to an apparent
association between vitamin D administration and better
survival. More studies including randomized trials are
needed to verify these associations.
MATERIALS AND METHODS
Patients
We examined prospectively collected data of a 2-year (1 July 2001–30
June 2003) historical cohort of all MHD patients from virtually all
DaVita Inc., dialysis facilities in the USA, the then second largest
dialysis care provider in the nation. The database creation has been
described elsewhere.29,30,32,39 This database included information on
approximately 40 000 maintenance dialysis patients at any given
time. All repeated measures for each patient within a given calendar
quarter (13-week interval) were averaged to obtain one quarterly
mean value and to mitigate the effect of short-term variations.
Hence, up to eight repeated and quarterly varying values were
available for each measure in each MHD patient over a 2-year
observation period. The study was approved by the Institutional
Review Committees of Harbor-UCLA and DaVita Inc.
Dialysis vintage was defined as the duration of time between the
first day of maintenance dialysis treatment anywhere and the first
day that the patient entered the cohort under the study. The entry
quarter was defined as the first calendar quarter in which patient’s
dialysis vintage was greater than 3 months for at least half of the
duration of the quarter. By implementing this criterion, any patient
who did not remain in the cohort beyond the first 3 months of
MHD was excluded.
Laboratory methods
All laboratory measurements were performed by DaVita Labora-
tories in Deland, FL, USA using standardized and automated
methods. For each laboratory measure, the mathematical average of
all available values within any given calendar quarter (13-week
intervals) was calculated and used in all analyses. Most blood
samples were collected pre-dialysis with the exception of the post-
dialysis serum urea nitrogen, which was obtained in order to
calculate urea kinetics. The normalized protein nitrogen appearance,
also known as protein catabolic rate, and Kt/V were calculated using
urea kinetic modeling formulas.40,41 Blood samples were drawn
using uniform techniques in all DaVita dialysis clinics across the
nation and were transported to the DaVita Laboratory in Deland,
Florida, USA, usually within 24 h of collection. Most laboratory
values, including complete blood cell counts and serum levels of
urea nitrogen, albumin, creatinine, calcium, phosphorus, bicarbo-
nate, iron, and total iron-binding capacity, were measured monthly.
Serum intact PTH (first-generation immunoradiometric PTH assay,
Nichols, San Juan Capistrano, CA, USA; Nussbaum et al.42) and
ferritin was usually measured at least once during each calendar
quarter. Both normalized protein nitrogen appearance and Kt/V
were calculated monthly. Hemoglobin was measured weekly to bi-
weekly in most patients. Serum calcium was adjusted for serum
albumin according to the following equation: adjusted cal-
cium¼measured calciumþ ((4.0serum albumin in g/dl) 0.8).
Laboratory measures of osteodystrophy were stratified a priori
similar to what was previously carried out by Block et al.10: (1)
albumin-adjusted serum calcium was divided into eight categories
of o8, X11 mg/dl, and six 0.5 g/dl groups in-between; (2) serum
phosphorus into eight categories of o3, X9 mg/dl, and six 0.5 g/dl
in-between; (3) the product of serum phosphorus and calcium into
12 categories of o40, X90, and ten 10 mg2/dl2 integers in-between;
(4) serum intact PTH into eight categories of o100, X700 pg/ml
and six 100 pg/ml groups in-between; and (5) serum alkaline
phosphatase into 10 categories of o50, X210 U/l, and eight 20 U/l
in-between.
The following nine time-varying (quarterly changing) laboratory
variables with up to eight repeated measures per patient over the 2-
year cohort time and with known associations with survival in
MHD patients were also included in the time-dependent Cox
models as time-varying surrogates of MICS: (1) serum albumin, (2)
normalized protein nitrogen appearance or normalized protein
catabolic rate, (3) serum total iron-binding capacity, (4) serum
creatinine, (5) serum bicarbonate, (6) serum ferritin, (7) blood
hemoglobin, (8) peripheral white blood cell count (WBC), and (9)
lymphocyte percentage.
Administered in-center medications
The averaged doses of the in-center (in dialysis facility) administered
vitamin D analogs paricalcitol (ZemplarTM) and calcitriol (Calcijex,
both from Abbott Laboratories, Abbott Park, IL, USA), which are
related to the management of renal osteodystrophy, were also
calculated in mg/week for each calendar quarter and included in all
case-mix adjusted models as additional time-varying covariates.
Paricalcitol per se was also examined as an independent predictor of
outcome in separate models (see below). The dose of administered
rHuEPO (EPOGEN, Amgen Inc., Thousand Oaks, CA, USA) was
also calculated for each calendar quarter in units/week and included
in the MICS-adjusted models as an indicator of inflammation.27,43,44
To examine the association between the administered paricalcitol
and survival in MHD patients, five groups of paricalcitol dose/status
were created a priori after excluding MHD patients who received
calcitriol or other vitamin D analogs (o4% together): (1) those who
did not receive any paricalcitol during the entire 13 weeks of a given
quarter; (2) those who received paricalcitol between 1 and 4.9mg/
week; (3) paricalcitol between 5 and 9.9 mg/week; (4) paricalcitol
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between 10 and 14.9 mg/week; and (5) paricalcitol of 15 mg/week or
greater.
Statistical and epidemiologic methods
For every time-varying measure, up to eight independent quarterly
values were obtained in each patient. Both fixed-covariate and time-
dependent Cox proportional hazard regression analyses (PROC
PHREG)45 were conducted to examine whether the 2-year survival
was associated with surrogates of bone disease. A hazard ratio
greater than 1.00 indicates increased death risk and below 1.00
implies improved survival chance. A 95% confidence interval
surpassing 1 is considered insignificant.
For each analysis, three types of models were examined based on
the level of multivariate adjustment: (1) unadjusted models included
indicators of osteodystrophy (calcium, phosphorus, calcium–pho-
sphorus product, intact PTH, or alkaline phosphatase) as the
predicting variable, entry quarter as the covariate, and mortality as
the outcome variable; (2) case-mix adjusted models included
additional covariates: age, gender, race and ethnicity, diabetes
mellitus, vintage, primary insurance, marriage status, and standar-
dized mortality ratio of the dialysis clinic during entry quarter,
continuous values of Kt/V, dialysate calcium concentration, and
administered doses of each of vitamin D analogs within each
calendar quarter; and (3) case-mix and MICS adjusted models
included all of the above-mentioned covariates plus 11 indicators of
nutritional status and inflammation including the time-varying
body mass index, averaged dose of rHuEPO in each calendar
quarter, and the nine above-mentioned time-varying laboratory
values (see above under Laboratory methods). All laboratory
markers, vitamin D analogs and rHuEPO dose, Kt/V, and body
mass index were included as time-varying covariates with up to eight
independent quarterly values per variable per each patient. When
paricalcitol dose was modeled as the predicting variable, time-
varying serum calcium, phosphorus, and intact PTH concentrations
were also included as additional case-mix covariates. Missing
covariate data (0 too2% for all variables, except for serum ferritin,
intact PTH, and body mass index) were imputed by the mean or
median of the existing values, whichever was most appropriate. For
the three variables with 42% missing values, a dummy variables
was created to indicate the missing status. All descriptive and
multivariate statistics were carried out with the SAS, version 8.02,
SAS Institute Inc., Cary, NC, USA. Owing to the large sample size,
most P-values tend to be small.
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